Key result
de Gramont's regimen (2 days infusional 5-FU) was associated with an overall cardiotoxicity incidence of 3.9% (9 of 231 patients), mostly occurring in the first cycle.
Why the study?
What is the incidence and clinical characteristics of cardiotoxicity in patients receiving de Gramont's regimen?
Population
231 patients receiving de Gramont's regimen
Design
Cohort
Authors
Loading...
Incidence data support early-cycle monitoring with de Gramont regimen; leaves open comparative cardiotoxicity risk versus longer 5-FU infusions.
Observational (n=231)
What is the incidence and clinical characteristics of cardiotoxicity in patients receiving de Gramont's regimen?
de Gramont's regimen has a 3.9% incidence of cardiotoxicity, which is lower than more prolonged 5-FU-based infusion regimens, but still requires careful monitoring during early cycles.
Nezih Meydan (2005) conducted an observational in Cancer (receiving 5-fluorouracil) (n=231). de Gramont's regimen (5-fluorouracil) was evaluated on Cardiac events (cardiotoxicity). de Gramont's regimen (2 days infusional 5-FU) was associated with an overall cardiotoxicity incidence of 3.9% (9 of 231 patients), mostly occurring in the first cycle.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: